Fudan University: Esophageal Squamous Cell Carcinoma trials

The registry lists 37 Esophageal Squamous Cell Carcinoma studies with Fudan University as lead sponsor. 11 are open to participants now and 0 have results posted.

Phase 2 19Phase 3 8No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCCRecruitingNCT07697859
• A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1 Therapy in Esophageal CancerNot yet recruitingNCT07573397
• Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07533357
• Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCCRecruitingNCT07403136Phase 2
• Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06703047Phase 2
• Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 InhibitorRecruitingNCT06190782Phase 3
• A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06152978Phase 2
• A Study of IO Plus Radiotherapy in Patients With Advanced ESCC.RecruitingNCT05760391Not applicable
• Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)RecruitingNCT05281003Phase 2
• Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)RecruitingNCT04519905Not applicable
• Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal CarcinomaRecruitingNCT03790553Phase 3
• an AI-Driven Four-Tier Invasion Depth Classification for Early Esophageal CancerActive, not recruitingNCT07605663
• TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06401447Not applicable
• Peripheral Blood Neoantigen Specific T Cells Predict the Efficacy of Immunotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT05633641
• ctDNA-based MRD Assessment in Local Advanced Esophageal CarcinomaStatus unknownNCT05426850
• Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709
• Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)Active, not recruitingNCT04764227Phase 2
• SIB in Upper Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04115618Phase 2
• Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCCCompletedNCT03985046Phase 2
• Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell CarcinomaCompletedNCT03904927Phase 2
• Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasCompletedNCT03797625Phase 2
• Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT03274011Phase 2
• Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection MarginStatus unknownNCT03273647Phase 3
• A Study of SBRT for OligoMetastatic ESCCCompletedNCT03000816Not applicable
• Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell CarcinomaCompletedNCT02916511Phase 2
• Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02677597Phase 3
• Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell CarcinomasStatus unknownNCT02665702Phase 2
• A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCCCompletedNCT02647125Phase 2
• A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal CancerCompletedNCT02459457Phase 3
• Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell CarcinomaStatus unknownNCT02384811Phase 2
• S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical StudyCompletedNCT01854749Phase 2
• Study of S-1 in Combination With Radiotherapy in Esophageal CancerCompletedNCT01831531Phase 2
• Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal CancerCompletedNCT01605305Phase 2
• A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal CarcinomaCompletedNCT01591135Phase 3
• Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyStatus unknownNCT01402180Phase 2/3
• Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0Status unknownNCT01398449Phase 3
• A Trial Estimating The Optimal Radiation Volume Of Postsurgical Radiation For Patients With Esophageal CancerStatus unknownNCT01391572Phase 2